CN114040908A - 一种凝血因子XIa抑制剂的晶型及其制备方法 - Google Patents
一种凝血因子XIa抑制剂的晶型及其制备方法 Download PDFInfo
- Publication number
- CN114040908A CN114040908A CN202080042070.7A CN202080042070A CN114040908A CN 114040908 A CN114040908 A CN 114040908A CN 202080042070 A CN202080042070 A CN 202080042070A CN 114040908 A CN114040908 A CN 114040908A
- Authority
- CN
- China
- Prior art keywords
- degrees
- compound
- crystal form
- ray powder
- powder diffraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种凝血因子XIa抑制剂的晶型及其制备方法，所述晶型的X射线粉末衍射图包含2θ角为6.9±0.2°，15.9±0.2°，21.8±0.2°，23.7±0.2°和28.2±0.2°的衍射峰。所述晶型具有较好的性能，稳定性高，可用于制备治疗心血管疾病的药物制剂。
Description
PCT国内申请，说明书已公开。
Claims (12)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019105543308 | 2019-06-25 | ||
| CN201910554330 | 2019-06-25 | ||
| PCT/CN2020/096572 WO2020259366A1 (zh) | 2019-06-25 | 2020-06-17 | 一种凝血因子XIa抑制剂的晶型及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114040908A true CN114040908A (zh) | 2022-02-11 |
Family
ID=74061200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080042070.7A Pending CN114040908A (zh) | 2019-06-25 | 2020-06-17 | 一种凝血因子XIa抑制剂的晶型及其制备方法 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114040908A (zh) |
| WO (1) | WO2020259366A1 (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999067215A1 (en) * | 1998-06-25 | 1999-12-29 | Bristol-Myers Squibb Company | Amidino and guanidino azetidinone tryptase inhibitors |
| US20040180855A1 (en) * | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| JP2005095167A (ja) * | 2003-08-26 | 2005-04-14 | Mitsubishi Chemicals Corp | 光学活性環状アミノ酸の製造方法 |
-
2020
- 2020-06-17 WO PCT/CN2020/096572 patent/WO2020259366A1/zh not_active Ceased
- 2020-06-17 CN CN202080042070.7A patent/CN114040908A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999067215A1 (en) * | 1998-06-25 | 1999-12-29 | Bristol-Myers Squibb Company | Amidino and guanidino azetidinone tryptase inhibitors |
| US20040180855A1 (en) * | 2003-02-19 | 2004-09-16 | Schumacher William A. | Methods of treating thrombosis with reduced risk of increased bleeding times |
| JP2005095167A (ja) * | 2003-08-26 | 2005-04-14 | Mitsubishi Chemicals Corp | 光学活性環状アミノ酸の製造方法 |
Non-Patent Citations (1)
| Title |
|---|
| XINHUA QIAN, ET AL.: "A Stereoselective Synthesis of BMS-262084, an Azetidinone-Based Tryptase Inhibitor", J. ORG. CHEM. * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020259366A1 (zh) | 2020-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014221831A (ja) | ４−メチル−ｎ−［３−（４−メチル−イミダゾール−１−イル）−５−トリフルオロメチル−フェニル］−３−（４−ピリジン−３−イル−ピリミジン−２−イルアミノ）−ベンズアミドの結晶形態 | |
| CN111377944A (zh) | Baloxavir marboxil晶型及其制备方法 | |
| US20240423955A1 (en) | Organic acid addition salts of s-pindolol | |
| WO2021129589A1 (zh) | Kd-025的新晶型及其制备方法 | |
| CN113912565A (zh) | 一种卡利拉嗪的新晶型及其制备方法 | |
| CN112638865B (zh) | 药物共晶体及其制备方法 | |
| CN114040908A (zh) | 一种凝血因子XIa抑制剂的晶型及其制备方法 | |
| CN114072406A (zh) | Flna-结合化合物及其盐酸盐的固体多晶型物 | |
| CN114591307B (zh) | 一种异喹啉类化合物硫酸盐晶型及其制备方法与应用 | |
| CN114591366B (zh) | 瑞德西韦的共晶及其制备方法 | |
| CN111689896A (zh) | 一种瑞戈非尼与戊二酸的共晶及其制备方法 | |
| CN115003657B (zh) | (-)-琥珀酸西苯唑啉的多晶型 | |
| CN114524845B (zh) | 瑞德西韦与水杨酸的共晶及其制备方法 | |
| CN110577522A (zh) | 马罗匹坦柠檬酸盐新晶型及其制备方法 | |
| CN114105867A (zh) | 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法 | |
| WO2024179558A1 (zh) | Pirtobrutinib的晶型及其制备方法和用途 | |
| WO2026013566A1 (en) | New salt forms of sabcomeline | |
| WO2026013563A1 (en) | New salt forms of sabcomeline | |
| WO2026013570A1 (en) | New salt forms of sabcomeline | |
| CN115124514A (zh) | Kd-025的共晶及其制备方法 | |
| HK40104833A (zh) | S-吲哚洛尔的有机酸加成盐 | |
| CN114105866A (zh) | 一种低氧诱导因子脯氨酰羟化酶抑制剂的晶型及其制备方法 | |
| WO2024153063A1 (zh) | Enpatoran的晶型及其制备方法和用途 | |
| CN115141143A (zh) | 一种酸的晶型及其制备方法 | |
| HK40081980B (zh) | S-吲哚洛尔的有机酸加成盐 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Address after: 523808 No.1, Gongye North Road, Songshanhu Park, Dongguan City, Guangdong Province Applicant after: Guangdong Dongyangguang Pharmaceutical Co.,Ltd. Address before: 523808 Songshan Lake Science and Technology Industrial Park, Dongguan City, Guangdong Province Applicant before: SUNSHINE LAKE PHARMA Co.,Ltd. |